Showing posts with label fourth. Show all posts
Showing posts with label fourth. Show all posts

Wednesday, May 29, 2013

Portland, Oregon Becomes Fourth American City To Adopt Paid Sick Day Law

Our guest blogger is Jane Farrell, a Research Assistant for economic policy at the Center for American Progress Action Fund.

Portland became the fourth American city to approve a paid sick days law Wednesday, an important step forward today that will help the city’s workers, employers, and residents. Portland joined three other cities – San Francisco, Washington DC, and Seattle – and one state, Connecticut, in modernizing its workplace policies and acknowledging an important reality: everybody gets sick but no one should be at risk of losing a job, infecting coworkers or customers, or missing a day’s pay because of an illness.

While the economic and social benefits of paid sick days are numerous, Portland City Councilmembers nevertheless weighed the evidence in favor of and against paid sick leave carefully. Ultimately, they unanimously decided that this policy would help make Portland a stronger city and community. Worker-friendly policies like paid sick leave help reduce turnover, saving businesses time and money they might have spent on training, hiring, and replacing employees. It also strengthens worker loyalty and increases worker productivity.

Paid sick leave also helps lower health care costs by reducing the number of costly emergency room visits Portland hospitals will have to finance or subsidize. While 40 percent of private sector workers across the US lack even one paid sick day, Portland residents who previously lacked this protection can now rest easy – and work even more diligently – knowing they are safe and covered.


View the original article here

Friday, March 1, 2013

UPDATE 1-Lilly loses ground in fourth quarter to generics

Jan 29 (Reuters) - Eli Lilly and Co said on Tuesday that fourth-quarter earnings fell as competition from generic drugs, particularly for its top-selling schizophrenia drug Zyprexa, drove revenue lower.

The U.S. drugmaker earned $827 million, or 74 cents per share, compared with $858 million, or 77 cents per share, a year earlier.

Excluding special items such as asset impairments and restructuring, Lilly earned 85 cents per share. Analysts, on average, were expecting 78 cents per share.

Revenue dropped by about 1 percent to $5.96 billion, above Wall Street expectations of $5.81 billion.

The company said falling sales from the loss of the Zyprexa patent was partly offset by gains in sales of other drugs and its animal health products.

Lilly said it expects earnings this year to increase to $3.82 to $3.97 per share, excluding special items. It said profit would benefit by 7 cents per share from a research and development tax credit that was delayed until this year due to the late signing of federal legislation.

It predicted sales will be flat to a bit higher this year, despite expected generic competition in December for its $5-billion-a-year antidepressant Cymbalta.


View the original article here